Variant · Expression
PDGFRA Overexpression
CI-VAR-00003200Explore in graph →CIViC 2944
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27582545
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| High-Grade Glioma, NOS1 | ||||||||
| PDGFRA Overexpression | Dasatinib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID7934Tumor cell line generated from pediatric high-grade glioma patient was found to have amplification of PDGFRA and FGF2. Gene expression of PDGFRA and FGF2 was found to be in the 99th percentile compare… (full text at CIViC) PMID 27582545 · Koschmann et al., 2016 · Open in CIViC | civic |
| Rhabdomyosarcoma1 | ||||||||
| PDGFRA Overexpression | Sunitinib | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID7988A high-throughput screen of 637 cancer cell lines revealed 2 to be sensitive to the multiple tyrosine kinase inhibitor, sunitinib. The most highly sensitive line was A-204, a rhabdomyosarcoma cell lin… (full text at CIViC) PMID 19366796 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available